BidaskClub upgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a buy rating to a strong-buy rating in a research report report published on Friday, July 14th.
A number of other equities analysts have also issued reports on the company. Canaccord Genuity lowered Entellus Medical from a buy rating to a hold rating and lowered their price target for the stock from $22.00 to $18.00 in a report on Thursday, May 4th. ValuEngine lowered Entellus Medical from a sell rating to a strong sell rating in a report on Tuesday, May 23rd. Zacks Investment Research lowered Entellus Medical from a hold rating to a sell rating in a report on Tuesday, May 9th. William Blair reaffirmed an outperform rating on shares of Entellus Medical in a report on Wednesday, May 10th. Finally, Piper Jaffray Companies reaffirmed a buy rating on shares of Entellus Medical in a report on Wednesday, July 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $21.83.
Shares of Entellus Medical (NASDAQ ENTL) traded down 1.40% during mid-day trading on Friday, hitting $16.86. The stock had a trading volume of 233,111 shares. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $22.63. The firm has a 50 day moving average price of $16.93 and a 200 day moving average price of $14.98. The firm’s market cap is $427.76 million.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The company had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. During the same period in the prior year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. Equities analysts predict that Entellus Medical will post ($1.62) EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of ENTL. Bank of America Corp DE increased its position in shares of Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after buying an additional 2,594 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares in the last quarter. First Mercantile Trust Co. increased its position in shares of Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after buying an additional 2,557 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after buying an additional 573 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Entellus Medical during the second quarter valued at about $199,000. Hedge funds and other institutional investors own 76.84% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
